2 January 2019 - Actelion has announced that NHS patients in England, who have the rare, incurable and devastating disease pulmonary arterial hypertension can now be treated with Uptravi (selexipag).

The drug is an oral treatment that specifically targets the prostacyclin pathway – a major disease pathway involved in the development of pulmonary arterial hypertension (PAH).

The decision comes after a Phase III clinical study of more than 1,000 people with the condition, in which it was shown shown to improve long-term outcomes for patients with PAH. A 40% reduction in the risk of a primary outcome event was seen in the patients.

Read Pharma Times article